iniparib
Jump to navigation
Jump to search
Indications
- improves outcomes in triple-negative* breast cancer when administered alongside standard chemotherapy
- androgen-independent metastatic prostate cancer
* estrogen receptor negative, progesterone receptor negative, HER2 negative
Mechanism of action
- inhibits poly(ADP)ribose polymerase (PARP), thus DNA repair of single-strand breaks
- unrepaired single strand breaks become double-strand breaks
- breast cancer patients with loss of BRCA1 or BRCA2 function are deficient in DNA double-strand break repair
- thus the PARP inibitor iniparib shows selective toxicity for tumor cells with homozygous BRCA1 or BRCA2 dysfunction
More general terms
References
- ↑ O'Shaughnessy EC et al Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer N Eng J Med January 5, 2011 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21208101 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1011418
Carey LA and Sharpless NE PARP and Cancer - If It's Broke, Don't Fix It N Eng J Med January 5, 2011 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21208102 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1012546